Kolmar BioTech (A215380) Stock Overview
Engages in the various research services in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A215380 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Kolmar BioTech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,210.00 |
| 52 Week High | ₩4,535.00 |
| 52 Week Low | ₩1,616.00 |
| Beta | 0.55 |
| 1 Month Change | -6.36% |
| 3 Month Change | -11.60% |
| 1 Year Change | 27.89% |
| 3 Year Change | -10.53% |
| 5 Year Change | -64.70% |
| Change since IPO | -61.48% |
Recent News & Updates
WOOJUNG BIO, Inc. (KOSDAQ:215380) Shares Fly 34% But Investors Aren't Buying For Growth
WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shares have had a really impressive month, gaining 34% after a shaky period...Health Check: How Prudently Does WOOJUNG BIO (KOSDAQ:215380) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Recent updates
Shareholder Returns
| A215380 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 5.2% | -3.1% | 7.1% |
| 1Y | 27.9% | -13.9% | 100.8% |
Return vs Industry: A215380 exceeded the KR Life Sciences industry which returned -13.9% over the past year.
Return vs Market: A215380 underperformed the KR Market which returned 100.8% over the past year.
Price Volatility
| A215380 volatility | |
|---|---|
| A215380 Average Weekly Movement | 7.4% |
| Life Sciences Industry Average Movement | 10.5% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.5% |
| 10% least volatile stocks in KR Market | 4.5% |
Stable Share Price: A215380 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A215380's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | ByungSeok Moon | kolmarbiotech.com |
Kolmar BioTech, Inc. engages in the various research services in South Korea. The company provides LAB CLOUD, a bio-specialized accelerator and research platform; and efficacy evaluation, clinical and histopathology, general and inhalation toxicology, behavioral test, bioanalytical, organoids, ADME, NMR analysis, SPR analysis, IND package, shared lab animal facility, breeding lab, microbial and environmental monitoring, and technical support services. In addition, It offers construction and implementation, infection control, maintenance, laboratory and pharmaceutical equipment, and consumables and animal resourcing services.
Kolmar BioTech, Inc. Fundamentals Summary
| A215380 fundamental statistics | |
|---|---|
| Market cap | ₩37.03b |
| Earnings (TTM) | -₩3.68b |
| Revenue (TTM) | ₩40.30b |
Is A215380 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A215380 income statement (TTM) | |
|---|---|
| Revenue | ₩40.30b |
| Cost of Revenue | ₩28.86b |
| Gross Profit | ₩11.44b |
| Other Expenses | ₩15.12b |
| Earnings | -₩3.68b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -218.47 |
| Gross Margin | 28.39% |
| Net Profit Margin | -9.12% |
| Debt/Equity Ratio | 226.6% |
How did A215380 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 12:21 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kolmar BioTech, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jae Hoon Shin | Hanwha Investment & Securities Co., Ltd. |